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INTRODUCTION
Nucleoside analogs are being effectively used in clinics for 
the management of cancer, either alone or in combination with 
other drugs [1,2]. Gemcitabine, also known as 2’, 2’-difluoro-de-
oxycytidine (dFdC), is a potent nucleoside analog used against 
a wide range of solid tumors [1,3-5]. Like other nucleoside ana-
logs, gemcitabine is transported to the cells by human equili-
brative and concentrative membrane transporters, where it is 
phosphorylated to the monophosphate form (dFdMP) by deox-
ycytidine kinase (dCK) [6]. dFdMP is further phosphorylated to 
cytotoxic diphosphate (dFdCDP) and triphosphate (dFdCTP) 
forms by intrinsic nucleotide kinases [7]. The diphosphorylated 
form of gemcitabine (dFdCDP) inhibits ribonucleotide reduc-
tase (RNR) causing a decrease in intracellular dCTP concentra-
tion. Consequently, increased phosphorylation of gemcitabine 
to its di and triphosphate forms occurs, leading to accelerated 
incorporation of dFdCTP into replicating DNA [8]. The tri-
phosphorylated form of gemcitabine incorporates into DNA, 
thereby causing chain termination and apoptosis [5,9].
Akin to other nucleoside analog-based chemotherapies, 
the clinical significance of dFdC is limited by the develop-
ment of drug resistance, either through intrinsic factors such 
as hypoxia, extracellular matrix transitions (EMT), and reac-
tive oxygen species (ROS)-induced changes, or by acquiring 
alterations in drug activation and metabolic pathways [10-16]. 
dCK plays an important role in the activation of gemcitabine 
through phosphorylation, and an altered expression of dCK 
has been correlated with the development of gemcitabine 
resistance both in vitro and in vivo [17-21]. Besides dCK, several 
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ABSTRACT
A recombinant deoxyribonucleoside kinase from Drosophila melanogaster with a deletion of the last 20 amino acid residues (named 
DmdNKΔC20) was hypothesized as a potential therapeutic tool for gene therapy due to its broad substrate specificity and better catalytic 
efficiency towards nucleosides and nucleoside analogs. This study was designed to evaluate the effect of DmdNKΔC20 for sensitizing human 
cancer cell lines to gemcitabine and to further investigate its role in reversal of acquired drug resistance in gemcitabine-resistant cancer cell line. 
The DmdNKΔC20 gene was delivered to three different cancer cell lines, including breast, colon and liver cancer cells, using lipid-mediated 
transfection reagent. After transfection, gene expression of DmdNKΔC20 was confirmed by quantitative reverse transcription PCR (qRT-PCR) 
and the combined effect of DmdNKΔC20 and gemcitabine based cytotoxicity was observed by cell viability assay. We further evolved a gem-
citabine-resistant breast cancer cell line (named MCF7-R) through directed evolution in the laboratory, which showed 375-fold more resis-
tance compared with parental MCF7 cells. Upon transfection with DmdNKΔC20 gene, MCF7-R cells showed 83-fold higher sensitivity to 
gemcitabine compared with the control group of MCF7-R cells. Moreover, we observed 79% higher expression of p21 protein in transfected 
MCF7-R cells, which may indicate induction of apoptosis. Our findings highlight the importance and therapeutic potential of DmdNKΔC20 in 
combined gene/chemotherapy approach to target a wide range of cancers, particularly gemcitabine-resistant cancers.
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other targets of gemcitabine metabolism have been associated 
with acquired resistance to gemcitabine [22,23]. One of those 
targets is cytidine deaminase (CDA), for which increased 
expression was associated with decreased sensitivity of cancer 
cells to gemcitabine both in vitro and in vivo. CDA converts 
dFdC to difluorodeoxyuridine (dFdU), thus contributing to 
gemcitabine resistance in cancer cells [24].
Different therapeutic approaches have been proposed 
to overcome resistance due to nucleoside kinase deficiency, 
such as the introduction of monophosphate derivatives of the 
nucleoside analogs into the cells or nucleoside kinase enzymes 
by gene therapy [20,25-30]. Gene-directed enzyme prodrug 
therapy (GDEPT), also called suicide gene therapy, has been 
shown to be more effective for specific targeting of cancer 
cells as compared to standard chemotherapy [31]. Suicide gene 
therapy has been employed successfully in conjunction with 
human dCK [22-25,27,28,31,32]; however, a non-human dNK, 
known as Herpes simplex 1 thymidine kinase (HSV1-TK), has 
also served as an archetype for this approach [33,34].
The kinetic properties of the kinases used in GDEPT 
approach are one of the limiting factors, therefore, a better cat-
alytic enzyme that could render more sensitivity to nucleoside 
analogs in cancer cells is desired. The landmark discovery of 
a multisubstrate nucleoside kinase from Drosophila melano-
gaster (called DmdNK), in 1998, ushered the kinases research 
into a new era. Based on its unique capacity to catalyze more 
efficiently the phosphorylation of all natural nucleosides and 
its substantial activity against a wide range of nucleoside 
analogs, DmdNK was distinguished among all nucleoside 
kinases for its potential use in suicide gene therapy [35,36]. 
The amino acid alignment data and structural knowledge of 
DmdNK show its structural similarity with non-TK1 fam-
ily of nucleoside kinases, which include mammalian TK2, 
dCK, and dGK [36,37]. Munch-Petersen et al. further studied 
recombinant DmdNK and generated its C-terminus trun-
cated versions called DmdNKΔC10, DmdNKΔC20, and 
DmdNKΔC30 by deleting the last 10, 20, and 30 amino acid 
residues, respectively [37]. The deletion of the last 20 amino 
acid residues from the C-terminus increased the specific activ-
ity by 2-fold, whereas the deletion of the last 30 C-terminal 
residues resulted in an almost inactive enzyme. Furthermore, 
DmdNKΔC20 was shown to be more stable than the wild-
type or full-length DmdNK [37].
DmdNK and its improved variants, produced by site-di-
rected mutagenesis, have been tested for their optimum appli-
cation in suicide gene therapy [38-40]. Both viral (adeno- and 
lentivirus-based vectors) and non-viral delivery systems 
have been used for transfecting different cancer cells with 
DmdNK and its mutants, to study the combined cytotoxic 
effect of gene/prodrug and to reverse drug resistance in var-
ious cancer cell lines [9,41-43]. To the best of our knowledge, 
DmdNKΔC20 has not been reported neither for sensitizing 
human cancer cell lines to gemcitabine nor for the reversal 
of gemcitabine resistance in drug-resistant cancer cells so far. 
Therefore, we studied the effect of DmdNKΔC20 to sensitize 
different human cancer cell lines to gemcitabine, and we fur-
ther elaborated its role in the reversal of acquired gemcitabine 
resistance due to dCK deficiency in the breast cancer cell line 
MCF7-R.
MATERIALS AND METHODS
Chemicals
Gemcitabine, MTT (methylthiazolyldiphenyl-tetra-
zolium bromide), and all other standard chemicals were 
purchased from Sigma-Aldrich, USA unless mentioned oth-
erwise. Cytarabine (araC) used in this study was obtained 
from Pfizer. GeneJet RNA purification kit (cat. # K0731), 
RevertAid first strand cDNA synthesis kit (cat. # K1622), and 
SYBR Green (cat. # K0221) were purchased from Thermo 
Fisher Scientific, USA. DMEM cell culture medium supple-
mented with Glutamax and sodium pyruvate (cat. # 1880272), 
fetal bovine serum (FBS), penicillin/streptomycin, Opti-
MEM™ (cat. # 1758537), trypsin, and cell culture grade  PBS 
were obtained from Gibco®  (Thermo Fisher Scientific, 
USA). Lipofectamine 3000® was purchased from Invitrogen (Thermo Fisher Scientific, USA). Primary antibodies were 
obtained from Santa Cruz Biotechnology, USA as follows: 
dCK (sc-81245), CDA (sc-365292), p21 (sc-756), and β-actin 
(sc-130656). The following secondary antibodies were used 
from Invitrogen: goat anti-mouse IgG, horseradish peroxi-
dase conjugate (Catalog No G21040) and goat anti-rabbit IgG, 
horseradish peroxidase conjugate (Catalog No G21234).
Cell culture
Breast cancer cell line MCF7, colon cancer cell line 
HCT116, and liver cancer cell line HePG2 were kindly pro-
vided by Professor Staffan Johansson (Department of Medical 
Biochemistry and Microbiology, Uppsala University, Sweden). 
MCF7  cells resistant to 2 µM gemcitabine (named MCF7-R) 
were evolved by exposing wild-type MCF7 (MCF7-wt) to grad-
ually increasing concentrations of gemcitabine over a period 
of 7 months. MCF7-R cells were viable in a medium contain-
ing 2 µM gemcitabine. The cancer cell lines used in this study 
were maintained in DMEM supplemented with 10% (v/v) FBS 
and penicillin/streptomycin (1%). Cells were grown in culture 
flasks with vented caps at 37°C in an incubator with 5% CO2.
Cell viability assay
Cell viability was analyzed by standard MTT assay. Cells 
from respective cell lines were seeded in triplicate with a 
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seeding density of 5000–7500 cells per well in 100 µl of fresh 
culture medium in 96-well plates. After 24 hours of incuba-
tion at 37°C, the culture medium was replaced with 100 µl of 
fresh medium containing different concentrations of either 
araC or gemcitabine depending on the experiment. In the 
presence of the candidate drug, cells were further incubated 
for 72 hours at 37°C under 5% CO2. After the incubation, 10 
µl of MTT (5  mg/ml) was added and the cells were further 
incubated at 37ºC for 4 hours. This resulted in the formation 
of formazan crystals due to mitochondrial dehydrogenase 
activity of viable cells; afterwards, the medium was replaced 
with 100 µl of acidified isopropanol (0.04N HCl in isopro-
panol) to dissolve the formazan crystals. The absorbance 
was recorded at 492 nm using Labtech LT-4500 plate reader. 
IC50 was defined as the drug concentration that reduces cell 
proliferation to 50% and calculated using equation 1. Survival 
curves were generated and analyzed by the non-linear regres-
sion function of GraphPad Prism 7 for Windows (GraphPad 
Software, La Jolla California USA). Resistance ratio was calcu-
lated as the ratio between IC50 of resistant cells to the IC50 of 
wild-type MCF7 cells.

50
Bottom+(Top Bottom)
Y=
(1+10^((Log IC X)*HillSlope)))  
(1)
Transfection of cancer cells with DmdNKΔC20
DmdNKΔC20 cloned in pGEX-2T vector was kindly pro-
vided by the late Professor Jure Piskur (Department of Biology, 
Lund University, Sweden). DmdNKΔC20 was restricted with 
BamH1 and EcoR1 and cloned into pcDNA3 vector. For trans-
fection studies, 70–80% confluent cancer cells were used. The 
cancer cells were transfected with pcDNA3 vector containing 
DmdNKΔC20 using Lipofectamine® 3000 reagent following 
the protocol described in Lipofectamine® 3000 reagent kit. For 
control groups, empty pcDNA3 vector was used for transfect-
ing the cancer cells using the same protocol. The transfected 
cells were incubated overnight before seeding into 96-well 
plates for cell viability assay (described earlier). Moreover, the 
total mRNA and protein of both groups of transfected cells 
were isolated 72 hours after the transfection for subsequent 
quantitative reverse transcription PCR (qRT-PCR) and west-
ern blot analyses.
Quantitative reverse transcription PCR (qRT-PCR)
The total mRNA was extracted from cells using GeneJet 
RNA purification kit according to the manufacturer’s proto-
col and quantified by NanoDrop™ 2000/2000c spectropho-
tometer (Thermo Fisher Scientific). After DNase-I treatment 
of template, 1  µg of cDNA was synthesized using the proto-
col of RevertAid first strand cDNA synthesis kit and used as 
a template in qRT-PCR employing SYBR Green chemistry 
for the detection of quantified product. The reaction was per-
formed in a thermal cycler (BioRad-CFX) with amplification 
profile as follows: initial denaturation at 95ºC for 10 minutes fol-
lowed by 40 cycles at 95ºC for 15 seconds, 58ºC for 20 seconds, 
and 72ºC for 20 seconds. The sequences of primers used for 
gene expression analysis in this study are provided in Table S1.
Western blot analysis
Total protein was extracted from transfected and control 
MCF7 groups using Laemmli method [44]. Proteins were 
separated by SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membrane for detection. Ponceau S stain-
ing was performed to verify the successful blotting of proteins 
on the PVDF membrane. Membranes were blocked using 
5% skimmed milk in TBST. After blocking, membranes were 
incubated with primary antibody against actin (1:250 dilution), 
dCK (1:50 dilution), CDA (1:1000 dilution), and p21  (1:500 
dilution) and further incubated with HRP-conjugated sec-
ondary antibodies (1:10,000 dilution). Protein signals were 
detected by chemiluminescence and exposed to Kodak films 
for quantification of the intensity of detected bands.
Statistical analysis
Each experiment was performed in triplicate and the 
results are expressed as the mean ± standard error (SE). 
Statistical analyses including Student’s t-test were performed 
using IBM SPSS Statistics for Windows, Version 23.0. (IBM 
Corp., Armonk, NY). Transfected and control groups were 
compared by paired t-test analysis using GraphPad Prism 7. 
Experiments with p < 0.05 were considered statistically signif-
icant and **** represents p < 0.0001.
RESULTS
Development and characterization of 2 µM 
gemcitabine-resistant cells
Gemcitabine-resistant MCF7 (MCF7-R) cells were 
evolved by exposing wild-type MCF7 cells to gradually increas-
ing concentrations of gemcitabine over a period of 7 months. 
The resulting MCF7-R cells showed 375-fold higher resistance 
to gemcitabine compared with wild-type (MCF7-wt) cells. 
Moreover, MCF7-R cells showed a significant cross-resistance 
to araC with a resistance ratio of 39-fold. The gene and pro-
tein expressions of enzymes dCK and CDA were estimated 
by qRT-PCR and western blot analysis, respectively (Figure 1). 
An altered expression of both dCK and CDA was observed 
in MCF7-R cells in comparison to the wild-type counter-
part. The gene expression of dCK was decreased to 2.7-fold 
in MCF7-R compared with wild-type  MCF7, whereas the 
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expression of CDA was 187-fold higher in MCF7-R cells com-
pared with near basal level expression of this enzyme in MCF7 
wild-type. Beta-2 microglobulin (B2M) gene expression was 
used as an internal control to normalize the expression of dCK 
and CDA. Similar changes in protein expression of the two 
enzymes were also observed in western blot analysis.
Determination of IC50 for gemcitabine and araC 
before transfection of DmdNKΔC20
IC50 for gemcitabine and araC were determined by MTT 
assay for breast, colon and hepatic cancer cell lines. The sur-
vival curves were generated and analyzed by non-linear 
regression analysis using GraphPad Prism 7 (Figure  2). IC50 
values for the cell lines determined in this study are shown in 
Table 1.
Effect of DmdNKΔC20 on wild-type and 
gemcitabine-resistant human cancer cell lines
The combined cytotoxic effect of suicide gene 
(DmdNKΔC20) and gemcitabine was studied using breast 
cancer (MCF7-wt and MCF7-R), colon cancer (HCT116) and 
hepatic cancer (HepG2) cell lines. The qRT-PCR results con-
firmed the expression of DmdNKΔC20 in transfected samples 
of each cell line. Human B2M expression was used as a refer-
ence for normalization (Figure 3).
MTT assay was performed to calculate the IC50 value for 
gemcitabine in each transfected cell line and compared with 
respective controls. Survival curves were generated (Figure 4) 
and data were analyzed by non-linear regression using 
GraphPad Prism 7.
FIGURE 1. (A) Gene expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in MCF7-wt and MCF7-R cell line was mea-
sured by quantitative reverse transcription PCR (qRT-PCR). Error bars represent standard error (SE). Two-tailed p values obtained by t-test, 
**** is p < 0.0001, *** is p < 0.001. (B) Protein expression of dCK and CDA was quantified by western blotting in MCF7-wt and MCF7-R 
cells, ß-actin was used as an internal control. An altered expression of both dCK and CDA was observed in MCF7-R cells in comparison 
to the wild-type counterpart. The gene expression of dCK was decreased to 2.7-fold in MCF7-R compared with wild-type MCF7, whereas 
the expression of CDA was 187-fold higher in MCF7-R cells compared with near basal level expression of this enzyme in MCF7 wild-type.
FIGURE 2. Cell viability of MCF7-wt, MCF7-R, HepG2, and HCT116 in the presence of gemcitabine and cytarabine (araC) was analyzed 
by MTT assay; each experiment was performed in triplicate. X-axis represents drug concentration and Y-axis represents cell survival in the 
presence of drug. Error bars represent standard error (SE).
A B
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sensitivity of each transfected cell line for gemcitabine are 
described in Table 2.
Furthermore, gemcitabine-resistant MCF7-R cells trans-
fected with DmdNKΔC20 became 83-fold more sensitive 
to gemcitabine than control, showing significant reversal of 
gemcitabine resistance upon transfection with DmdNKΔC20. 
A  comparison of IC50 ratios of control and transfected 
MCF7-R cells provided extremely significant statistical results 
(paired t-test was performed as mentioned in Table 2).
Detection of p21 protein as apoptotic marker
Previous studies showed the role of p21 protein in growth 
arrest and induction of apoptosis by either p53 dependent or 
independent activation pathways and indicated that its upreg-
ulation in cancer cell lines is probably a consequence of anti-
cancer treatment [45-48]. The western blot analysis using cell 
lysates showed 79% higher level of p21 protein expression in 
transfected MCF7-R cells compared with the control, which 
may indicate the induction of apoptosis as described earlier 
(Figure 5). The p21 specific primary antibody expression was 
normalized against ß-actin.
DISCUSSION
Gemcitabine is a potent nucleoside analog, which has 
been shown to have substantial anticancer activity against a 
wide range of solid tumors [5,9]. Due to its low toxicity profile, 
gemcitabine has also been recommended as an effective drug 
for use in suicide gene therapy [49]. The truncated variant 
TABLE  1. IC
50
 values (in µM) for nucleoside analog effect on 
different cancer cell lines before transfecting DmdNKΔC20
Cancer cell line IC50 for gemcitabine IC50 for araC p
MCF7-wt 0.004±0.00071 3.5±0.0003 ****
MCF7-R 1.5±0.00017 138±0.0092 ****
HCT116 0.082±0.00039 0.1735±0.00039 ****
HePG2 2.9±0.002 0.093±0.00029 ****
All experiments are representative values of triplicate assay and results 
are expressed as mean values±SE. ****indicates statistically highly signif-
icant (p<0.0001), obtained by Student’s t-test. ****represents statistically 
significant p<0.0001, for 2 µM gemcitabine-resistant MCF7 and wild-type 
MCF7 cells. SE: Standard error
FIGURE 3. Expression of DmdNKΔC20 in human cancer cell lines 
after transfection, measured by quantitative reverse transcription 
PCR (qRT-PCR). Error bars represent standard error (SE).
FIGURE 4. Cell viability of MCF7-wt, MCF7-R, HepG2, and HCT116 cancer cells after transfection with DmdNKΔC20; each experiment was 
performed in triplicate. Error bars represent standard error (SE). The results were further analyzed by Prism’s paired t-t est analysis. **** 
represents p < 0.0001. A significant increase in the sensitivity of transfected cell lines to gemcitabine upon transfection of DmdNKΔC20 
was observed, as shown by a decrease in IC
50
 compared with control group.
A significant increase in the sensitivity of transfected cell 
lines to gemcitabine was observed, as shown by a decrease 
in IC50 compared with control group. The IC50 and folds of 
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higher than previously reported for human uterine sar-
coma cell line Messa 10K, where a full-length DmdNK was 
transfected to sensitize human cancer cell lines to various 
nucleosides [9,41-43, 50-52]. A  possible explanation for the 
increased sensitivity to gemcitabine is the lower Km value of 
DmdNKΔC20 for this analog and unique interaction of fluo-
ride atoms of gemcitabine [40]. The strong binding affinity of 
DmdNKΔC20 towards gemcitabine enhances the phosphor-
ylation of gemcitabine that may result in an increased apop-
tosis with high p21 protein expression in transfected cells, as 
observed in Figure 5.
The results shown in this study are comparable to previ-
ously reported results in which a full-length DmdNK with dif-
ferent nucleoside analogs has been used [5,9,20,26,27,53-55]. 
However, our findings emphasize the role of the truncated 
version of Drosophila melanogaster enzyme, DmdNKΔC20, 
in sensitizing different cancer cells to gemcitabine and elabo-
rate its role in the reversal of gemcitabine resistance in MCF7 
cancer cells in vitro. These findings may be useful for future 
studies aiming to explore the potential use of DmdNKΔC20 
in combined enzyme/prodrug therapeutic approach in treat-
ing a wide range of cancers, particularly gemcitabine-resistant 
cancers.
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TABLE S1. Primers used in qRT-PCR experiments
Target gene Forward primer (5’-3’) Reverse primer (5’-3’)
dCK TCCATCGAAGGGAACATCGC CATCTGGCAACAGGTTCAGGA
CDA TCGCCAGTGACATGCAAGAT CCATCCGGCTTGGTCATGTA
DmdNKΔC20 TGACCATGCTGCAGTCGCACA CGCATGTTCTCCACGAAGCAA
B2M TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT
dCK: Deoxycytidine kinase; CDA: Cytidine deaminase; B2M: Beta-2 microglobulin; qRT-PCR: Quantitative reverse transcription polymerase chain reaction 
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